PD-L1 expression and prognostic impact in glioblastoma

BACKGROUND: Therapeutic targeting of the immune checkpoints cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4) and PD-1/PD-L1 has demonstrated tumor regression in clinical trials, and phase 2 trials are ongoing in glioblastoma (GBM). Previous reports have suggested that responses are more frequen...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Nduom, Edjah K., Wei, Jun, Yaghi, Nasser K., Huang, Neal, Kong, Ling-Yuan, Gabrusiewicz, Konrad, Ling, Xiaoyang, Zhou, Shouhao, Ivan, Cristina, Chen, Jie Qing, Burks, Jared K., Fuller, Greg N., Calin, George A., Conrad, Charles A., Creasy, Caitlin, Ritthipichai, Krit, Radvanyi, Laszlo, Heimberger, Amy B.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2016
Aiheet:
Basic and Translational Investigations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4724183/
https://ncbi.nlm.nih.gov/pubmed/26323609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nov172
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia